Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Ochi H, Kurosaki M, Joko K, Mashiba T, Tamaki N, Tsuchiya K, Marusawa H, Tada T, Nakamura S, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kusakabe A, Furuta K, Kobashi H, Arai H, Nonogi M, Tamada T, Hasebe C, Izumi N.
Ochi H, et al. Among authors: kurosaki m.
Hepatol Res. 2023 Jan;53(1):61-71. doi: 10.1111/hepr.13836. Epub 2022 Oct 4.
Hepatol Res. 2023.
PMID: 36070216